1126795-00-3

Usage

Uses

As the information provided is limited, the potential uses of 3-Oxa-9-azabicyclo[3.3.1]nonan-7-one Hydrochloride can only be speculated based on its classification as an azabicyclo compound. It is likely that 3-Oxa-9-azabicyclo[3.3.1]nonan-7-one Hydrochloride may be used in various applications within the medical and pharmaceutical industries, such as:
Used in Pharmaceutical Industry:
3-Oxa-9-azabicyclo[3.3.1]nonan-7-one Hydrochloride may be used as an active pharmaceutical ingredient for the development of new drugs, given its biological activities. The exact application reason would depend on the specific properties and effects of the compound once they are fully understood.
Used in Medical Research:
3-Oxa-9-azabicyclo[3.3.1]nonan-7-one Hydrochloride could also be utilized in medical research as a potential candidate for studying its interactions with biological systems, which may lead to the discovery of new therapeutic applications or insights into disease mechanisms.

Upstream product

• 926658-87-9 3-oxa-9-azabicyclo[3.3.1]nonan-7-one 
• 280761-97-9 tert-butyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 81514-40-1 N-benzyl-7-oxa-9-azabicyclo<3.3.1>nonan-3-one 

Downstream Products

• 280761-97-9 tert-butyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 81514-40-1 N-benzyl-7-oxa-9-azabicyclo<3.3.1>nonan-3-one 

Relevant academic research and scientific papers

SUBSTITUENT-INCLUDING UREA COMPOUND

An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases. The present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. (Each symbol in Formula (1) has the same definition as that described in the specification.)

3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES

A compound of formula Ia, Ib, Ic or Id: wherein: n is 1 or 2;R N is H or Me; R1 is optionally one or more halo or methyl groups;R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH2 OH; R 2c and R 2d (if present) are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and(iv) CH 2 OH;R 3a and R 3b are independently selected from H and Me; R 4a is selected from OH,-NH 2, -C(=O)NH 2, and -CH 2 OH; R 4b is either H or Me; R5 is either H or Me; m is 1 or 2; q is 0 or 1;R 11a, R 11b, R 11c and R 11d are independently selected from H, halo, C1-4 alkyl, C 1-4 fluoroalkyl, C 3-4 cycloalkyl, C 1-4 alkyloxy, NH-C 1-4 alkyl and cyano; R 12a and R 12b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH 2 OH; R 12c and R 12d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH 2 OH;R 12e is H or Me; R 13a and R 13b are independently selected from H and Me; R 14 is either H or Me; R 16a and R 16b are independently selected from H and Me; R 6 is selected from H, OMe, and OEt.

SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF

The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administeri

BRIDGED N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE

The invention provides N-cyclic sulfonamido compounds and salts of Formula (I): wherein A is as described in the specification and R1 and R2combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula (I) are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula (I).